A PYMNTS Company

EU: Commission takes action against household pharma cos

By  |  February 1, 2013

The European Commission is reportedly set to investigate Johnson & Jonson and Novartis over claims the two pharmaceutical companies partook in anticompetitive policies and practices through squeezing out a generic painkiller competitor. The allegations consist of the companies’ Dutch subsidiaries colluding to keep generic fentanyl off the shelves after J&J’s patent protection on the branded drug expired. The EC has reportedly filed its first action against the companies in the form of a statement of objections. These types of pay-for-delay agreements have been under consideration from the Commission for several years; an industry-wide probe into the matter began in 2008.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

     

    Full content: PMLive

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.